Arcadia Biosciences, Inc. short interest in 2021
In 2021, Arcadia Biosciences, Inc.'s disclosed short interest ran from 1.90% of shares outstanding on 15 Jan 2021 to 3.97% on 31 Dec 2021, a change of +2.07 percentage points. The year's high was 7.90% on 15 Apr 2021 and its low 1.90% on 15 Jan 2021, averaging 5.16% across 20 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.19 days on 15 Sep 2021. Full history: Arcadia Biosciences, Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2021 in figures
- Start of year
- 1.90% (15 Jan 2021)
- End of year
- 3.97% (31 Dec 2021)
- Change
- +2.07 pp
- High
- 7.90% (15 Apr 2021)
- Low
- 1.90% (15 Jan 2021)
- Average
- 5.16%
- Highest days to cover
- 9.19 (15 Sep 2021)
- SEC filings marked
- 8
Every report in 2021
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2021 | 1.90% | 1.00 | |
| 31 Mar 2021 | 5.62% | 1.00 | results (8-K), 10-K filed |
| 15 Apr 2021 | 7.90% | 1.33 | |
| 30 Apr 2021 | 6.38% | 1.00 | |
| 14 May 2021 | 6.23% | 1.99 | |
| 28 May 2021 | 5.23% | 1.73 | 10-Q filed, results (8-K) |
| 15 Jun 2021 | 4.75% | 1.55 | |
| 30 Jun 2021 | 5.39% | 1.02 | |
| 15 Jul 2021 | 6.10% | 2.41 | |
| 30 Jul 2021 | 5.79% | 3.12 | |
| 13 Aug 2021 | 6.00% | 7.70 | |
| 31 Aug 2021 | 6.46% | 2.90 | 10-Q filed, results (8-K) |
| 15 Sep 2021 | 6.28% | 9.19 | |
| 30 Sep 2021 | 4.38% | 5.00 | |
| 15 Oct 2021 | 4.02% | 5.68 | |
| 29 Oct 2021 | 4.47% | 2.05 | |
| 15 Nov 2021 | 4.76% | 2.91 | 10-Q filed, results (8-K) |
| 30 Nov 2021 | 3.87% | 2.02 | |
| 15 Dec 2021 | 3.65% | 2.62 | |
| 31 Dec 2021 | 3.97% | 1.55 |
See also: Arcadia Biosciences, Inc.'s full history · most shorted US stocks of 2021 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.